PMID- 17598908
OWN - NLM
STAT- MEDLINE
DCOM- 20070830
LR  - 20181201
IS  - 1471-2164 (Electronic)
IS  - 1471-2164 (Linking)
VI  - 8
DP  - 2007 Jun 28
TI  - A gene transcription signature associated with hormone independence in a subset 
      of both breast and prostate cancers.
PG  - 199
AB  - BACKGROUND: The development of resistance to hormone therapy in both breast and 
      prostate cancers is attributed to tens of thousands of patient deaths every year. 
      RESULTS: From analyses of global gene expression profile data, a nonrandom amount 
      of overlap was observed between the set of genes associated with estrogen 
      receptor negative (ER-), hormone independent breast cancer and the set of genes 
      associated with androgen independent (AI) prostate cancer. A set of 81 genes was 
      identified that were differentially expressed between ER- and ER+ clinical breast 
      tumors and breast cancer cell lines and that showed concordant expression in AI 
      versus AS (androgen sensitive) prostate cell lines. This common gene signature of 
      hormone independence was used to identify a subset of clinically localized 
      primary prostate tumors that shared extensive similarities in gene transcription 
      with both ER- breast and AI prostate cell lines and that tended to show 
      concurrent deactivation of the androgen signaling pathway. Both ER- breast and AI 
      prostate cell lines were significantly enriched for transcriptional targets of 
      signaling via epidermal growth factor receptor (EGFR). CONCLUSION: This study 
      indicates that the growth- and survival-promoting functions of hormone receptors 
      can be bypassed in a subset of both breast and prostate cancers by the same 
      growth factor signaling pathways, which holds implications for the use of 
      targeted therapy regimens.
FAU - Creighton, Chad J
AU  - Creighton CJ
AD  - Department of Medicine, Dan L. Duncan Cancer Center Division of Biostatistics, 
      Baylor College of Medicine, Houston, TX 77030, USA. creighto@bcm.tmc.edu
LA  - eng
PT  - Journal Article
DEP - 20070628
PL  - England
TA  - BMC Genomics
JT  - BMC genomics
JID - 100965258
RN  - 0 (Hormones)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Breast Neoplasms/drug therapy/*genetics
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*genetics
MH  - ErbB Receptors
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Hormones/*pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/drug therapy/*genetics
MH  - Receptors, Androgen
MH  - Receptors, Estrogen
MH  - Signal Transduction
MH  - Transcription, Genetic
MH  - Tumor Cells, Cultured
PMC - PMC1914359
EDAT- 2007/06/30 09:00
MHDA- 2007/08/31 09:00
PMCR- 2007/06/28
CRDT- 2007/06/30 09:00
PHST- 2007/03/12 00:00 [received]
PHST- 2007/06/28 00:00 [accepted]
PHST- 2007/06/30 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/06/30 09:00 [entrez]
PHST- 2007/06/28 00:00 [pmc-release]
AID - 1471-2164-8-199 [pii]
AID - 10.1186/1471-2164-8-199 [doi]
PST - epublish
SO  - BMC Genomics. 2007 Jun 28;8:199. doi: 10.1186/1471-2164-8-199.